Biotechnology · NYSE

ABBVAbbVie Inc.

Last close
$295.03 +0.2%
52-week range
$190.75 to $302.93
Market cap
$521B
Next earnings
Not scheduled

Fiscal 2025 at a glance

Revenue
$61.2B
+9% vs FY24
Net income
$4.23B
-1% vs FY24
Free cash flow
$17.8B
-0% vs FY24
Net cash
-$62.2B
Cash $5.26B, debt $67.5B

Stock price

+379% since Dec 2016

Valuation vs its own 10 years

Above its 10-year median on all 4 multiples

Where each multiple sits today inside its own range since 2016, measured at every quarter end. The thin tick is the median.

P/E, trailing
50.8x
13.5x175x
72nd percentile, above its median of 27.2x
Price / sales
7.9x
3.3x7.9x
Highest point in its range, above its median of 4.7x
EV / EBITDA
26.9x
9.9x48.3x
75th percentile, above its median of 19.5x
Price / free cash flow
27.6x
8.3x27.6x
Highest point in its range, above its median of 12.4x

Key statistics

Trailing 12 months unless noted, through the quarter ending 2026-09-30. Every figure carries its unit.

Valuation

P/E
50.8x
Earnings yield
2.0%
Price / sales
7.9x
Price / book
n/aNot reported
Price / operating cash flow
26.0x
EV / EBITDA
26.9x
EV / sales
9.0x
Free cash flow yield
3.6%

Profitability

Gross margin
73.7%
Operating margin
32.2%
Net margin
15.7%
Return on equity
n/aNegative equity
Return on capital
22.5%

Growth per year

Revenue, 3 years
+1.8%
Revenue, 5 years
+6.0%
Revenue, 9 years
+10.1%
EPS, 3 years
-29.1%

Balance sheet

Cash and investments
$10.8B
Total debt
$80.9B
Net cash
-$70.1B
Debt / equity
n/aNegative equity
Current ratio
0.87x

Shares and dividend

Shares outstanding
1.77B
Share count, 5 years
+6.0%
Beta, 1 year
-0.02
Dividend yield
2.3%
Dividend per share, TTM
$6.92
Payout ratio
117%

Ten years of the business

Last 40 quarters, fiscal 2016 to 2025 and after. Hover a bar for its quarter.

Revenue and net incomeLatest quarter $17.4B
RevenueNet income
Gross profitLatest quarter $13.1B
EBITDALatest quarter $6.46B
Margins75 / 36 / 24%
GrossOperatingNet
Earnings per shareLatest quarter $2.37
Cash flowLatest quarter $7.61B
OperatingCapexFree
Cash vs debtLatest quarter $10.8B
Cash and investmentsTotal debt
P/E historyNow 50.8x
P/E, median 27.2x dashed
P/S historyNow 7.9x
P/S, median 4.7x dashed

Biotechnology peers

The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.

CompanyMarket capRevenue growth Operating marginP/EP/SP/E vs own history
ONC BeOne Medicines Ltd. $619B +33% 17.8%689x93.6x Not enough history
ABBV AbbVie Inc. $521B +11% 32.2%50.8x7.9x 72nd percentile
AMGN Amgen Inc $252B +8% 32.4%27.0x6.5x 78th percentile
GILD Gilead Sciences, Inc. $208B +7% -7.6%No earnings6.7x No earnings
VRTX Vertex Pharmaceuticals Inc / Ma $137B +10% 33.2%34.7x10.5x 71st percentile
MRNA Moderna, Inc. $90.4B +13% -116%No earnings35.8x No earnings

The company

Sector
Health Care
Industry
Biotechnology
CEO
Richard A. Gonzalez
Founded
2012
Headquarters
North Chicago, IL
Fiscal year ends
December
Website
abbvie.com

What it does

AbbVie Inc., also known as AbbVie, is an American pharmaceutical company headquartered in North Chicago, Illinois. AbbVie produces drugs to treat a wide range of medical issues.

Description from Wikipedia (CC BY-SA).

Around the numbers

What the rest of EdgeStacker knows about ABBV.

Next report

No confirmed report date in the next 95 days yet.

Open the Earnings Hub
Big funds, latest 13F

Held by 3,905 active funds. Crowd level: quiet.

Open the Smart money tab